echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Keytruda combination therapy for gastric cancer Murshadon reaches clinical trial partnership

    Keytruda combination therapy for gastric cancer Murshadon reaches clinical trial partnership

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Under the terms of the agreement, Dinghang Pharma will conduct a one-arm open label Phase 2 clinical study aimed at evaluating the effectiveness and safety of the combination therapy for patients with advanced gastric cancer and esophageal gastric combination cancer who have undergone at least one failed pre-treatmentThe study is expected to begin in the second half of 2019, recruiting about 80 patientsBavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS)PS is phospholipid exposed to the surface of stress cells in tumors and their substratesBavituximab blocks the binding of PS with a variety of immune cell receptors, including TIM and TAM, reversing the PS-mediated immunosuppression processThere have been trials that have shown that PS-targeted antibodies can alter the function of immune cells in tumors and stimulate the performance of multiple immune activation sororiasis and antitumor immune responsesThis mechanism can also allow other cancer therapies to attack tumors more effectively and without restrictionImportantly, bavituximab has demonstrated its controlled safety and tolerance in clinical trials completed to dateThe PS on the surface of thecell is an immune checkpoint (Image Source: References)Keytruda is a human-derived PD-1 monoclonal antibody that blocks the binding of the PD-1 receptor on the surface of T cells to its ligand, activating the T-cell and allowing it to attack the tumorThe weight-heavy therapy has been expanding its indications since it was approved for the treatment of melanoma in 2014note: The original text has a limitationReferences:, Oncology, IncAnnounces Clinical Trial Collaboration Merck to Evaluate Bavituximab in Combination with KEYTRUDa ® (Pembrolizumab) in Advanced Gastrior Gastroeal Cancer Retrieved Aug 12, 2019, from Retrieved Aug 12, 2019 from
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.